All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-02-25T13:09:37.000Z

TCT Meeting 2019 | Salivary zymogen granule protein 16B is a potential salivary biomarker for oral chronic graft-versus-host disease

Feb 25, 2019
Share:

Bookmark this article

On 21 February 2019, Jacqueline W. Mays from the National Institutes of Health, Bethesda, MD, USA, presented results on behalf of colleagues of a study evaluating whole saliva for the presence of a diagnostic biomarker profile at first onset of oral chronic graft-versus-host disease (cGvHD) prior to initiation of topical steroid therapy at the 2019 TCT Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR in Houston, Texas, USA.

Patients and methods

  • Samples were collected at oral cGvHD onset from NIH protocols: NCT00331968, NCT00520130, or NCT01851382
  • Patients had biopsy-proven oral GvHD
  • Kruskal-Wallis test was used for protein identification
  • Selected proteins were validated by Western blot (WB) in two independent cohorts
  • Cohort 1: post-hematopoietic stem cell transplantation (HSCT) patients with (n = 10) and without (n = 10) oral cGvHD
  • Cohort 2: post-HSCT patients with (n = 12) and without (n = 12) oral cGvHD

Key findings

  • The dataset included 569 confidently-identified proteins, with 77 significantly differentially expressed at the onset of cGvHD
  • Zymogen granule protein 16B (ZG16B) was reduced 2-fold in the saliva of post-HSCT patients with oral cGVHD (898.1 ± 371.8 AU) compared with post-HSCT patients without oral cGVHD (1905 ± 598.6 AU) P< 0.05)
  • Immunohistochemically (IHC) staining for ZG16B demonstrated a significant decrease in ZB16B protein expression in patient labial salivary gland tissue after oral cGVHD onset

Conclusion

Jacqueline W. Mays concluded that ZG16B is present in lower amounts in unstimulated whole saliva and within the salivary gland acinar units at oral cGvHD onset. Reduction in the ZG16B protein may indicate cGvHD activity as well as potentially causing salivary gland damage. Dr. Mays added that further investigation in a larger cohort is required to assess whether saliva can be used to identify a diagnostic biomarker profile for oral cGvHD.

  1. Costa da Silva A.C. et al. Salivary zymogen granule protein 16B drops at onset of chronic graft-versus-host disease: a possible salivary biomarker for oral chronic graft-versus-host disease. 2019 Feb 21; Oral Abstract #32: 2019 TCT Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR, Houston, Texas, USA.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox